Spots Global Cancer Trial Database for leukemia
Every month we try and update this database with for leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE) | NCT03099031 | Venous Thromboe... | Tinzaparin | 18 Years - | LEO Pharma | |
| Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy | NCT00728520 | Acute Myeloid L... Elderly | Azacitidine | 60 Years - | Kansas City Veteran Affairs Medical Center | |
| Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome | NCT00003171 | Leukemia Myelodysplastic... | bryostatin 1 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia | NCT04856215 | Leukemia | 90-Yttrium-labe... | 6 Months - 18 Years | Great Ormond Street Hospital for Children NHS Foundation Trust | |
| Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia | NCT00643240 | Leukemia | yttrium Y 90 an... 111In-BU-12 | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Exercise Program for Adolescents and Young Adults With Cancer | NCT00502749 | Leukemia Lymphoma | Exercise progra... Questionnaires | 12 Years - 25 Years | M.D. Anderson Cancer Center | |
| Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer | NCT00312429 | Hematologic Neo... | Stem Cell Trans... | 18 Years - 70 Years | Duke University | |
| Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia | NCT00021983 | Leukemia | BL22 immunotoxi... | 18 Years - | National Cancer Institute (NCI) | |
| Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine | NCT00058799 | Leukemia | Dose Level 1 Dose Level 2 Dose Level 3 | - 75 Years | Baylor College of Medicine | |
| Neurocognitive and Psychosocial Outcomes in Survivors of Childhood Leukemia With Down Syndrome | NCT02859389 | Leukemia Down Syndrome | - | St. Jude Children's Research Hospital | ||
| Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant | NCT06315309 | GVHD,Acute Acute Leukemia Myelodysplastic... Myeloproliferat... | ATG Combined wi... | 18 Years - 60 Years | University of Alabama at Birmingham | |
| Study of the Physical and Emotional Needs of Parents Caring for Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia | NCT00056069 | Leukemia | questionnaire a... | - | Children's Oncology Group | |
| Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia | NCT00436904 | Leukemia | Alemtuzumab Rituximab | 18 Years - | Mayo Clinic | |
| Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia | NCT01229956 | Leukemia | DNA methylation... gene expression... microarray anal... reverse transcr... laboratory biom... | 1 Year - 18 Years | Children's Oncology Group | |
| A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia | NCT00001689 | Acute Lymphocyt... Leukemia | Vincristine | - | National Institutes of Health Clinical Center (CC) | |
| Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia | NCT00324779 | Leukemia Lymphoma | rituximab | - 18 Years | National Cancer Institute (NCI) | |
| Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia | NCT00003868 | Leukemia | cyclophosphamid... methotrexate allogeneic bone... peripheral bloo... iodine I 131 mo... radiation thera... | 2 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors | NCT01913093 | Childhood Leuke... | 8 Years - 20 Years | The Hospital for Sick Children | ||
| Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia | NCT00002549 | Leukemia | filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mesna mitoxantrone hy... allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | NCT04809467 | Chronic Lymphoc... Non Hodgkin Lym... | tafasitamab parsaclisib | 18 Years - | Incyte Corporation | |
| Oral Valganciclovir Versus Valacyclovir | NCT00562770 | Chronic Lymphoc... Leukemia | Valganciclovir Valacyclovir | 16 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia | NCT00040690 | Leukemia Lymphoma | filgrastim cyclophosphamid... cytarabine doxorubicin hyd... etoposide ifosfamide leucovorin calc... methotrexate vincristine sul... radiation thera... | 16 Years - | National Cancer Institute (NCI) | |
| Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies | NCT00795132 | Acute Leukaemia Chronic Disease Leukemia Myelodysplasia Lymphoma | Busulfan Anti-Thymocyte ... Fludarabine Cyclosporine Mycophenolate m... | - 21 Years | University of Utah | |
| Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | NCT00759603 | Chronic Lymphoc... Small Lymphocyt... | Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer | NCT00002742 | Chronic Myelopr... Infection Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | amphotericin B ... nystatin | 2 Years - | National Cancer Institute (NCI) | |
| Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment | NCT02099266 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Hodgkins Lympho... Non-Hodgkins Ly... | Administration ... | 17 Years - 70 Years | University of Kansas Medical Center | |
| Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia | NCT00006090 | Leukemia | arsenic trioxid... | 12 Years - | M.D. Anderson Cancer Center | |
| Granulocyte Transfusions After Umbilical Cord Blood Transplant | NCT05425043 | Pediatric Cance... | Granulocytes | - 16 Years | University of Manchester | |
| Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia | NCT00021983 | Leukemia | BL22 immunotoxi... | 18 Years - | National Cancer Institute (NCI) | |
| Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy | NCT00310115 | Bladder Cancer Cervical Cancer Esophageal Canc... Gastric Cancer Head and Neck C... Kidney Cancer Leukemia Liver Cancer Lung Cancer Pancreatic Canc... Tobacco Use Dis... | Smoking Prevent... Counseling Inte... Counseling Inte... | 18 Years - | M.D. Anderson Cancer Center | |
| Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation | NCT00003056 | Leukemia Lymphoma Graft Versus Ho... | cyclosporine cyclosporine an... | 18 Years - 55 Years | Takeda | |
| Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia | NCT00002785 | Leukemia | filgrastim asparaginase cyclophosphamid... cyclosporine cytarabine daunorubicin hy... dexamethasone etoposide leucovorin calc... mercaptopurine mesna methotrexate methylprednisol... pegaspargase prednisone therapeutic hyd... vincristine sul... allogeneic bone... low-LET cobalt-... low-LET photon ... | - 1 Year | Children's Oncology Group | |
| Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia | NCT00896766 | Leukemia | loss of heteroz... microarray anal... polymorphism an... tumor replicati... | 1 Year - 21 Years | Children's Oncology Group | |
| Peppermint Inhalation Versus Swedish Massage on Chemotherapy Induced-Nausea and Vomiting in Children With Leukemia | NCT06095726 | Leukemia | Peppermint Inha... Swedish Massage | 6 Years - 15 Years | Alexandria University | |
| Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI | NCT00363649 | Leukemia | GM-K562 cell va... Interferon alfa Sargramostim | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer | NCT00546377 | Leukemia Lymphoma | filgrastim pegfilgrastim rituximab sargramostim cyclophosphamid... mitoxantrone hy... pentostatin fluorescence in... gene rearrangem... polymerase chai... protein express... flow cytometry biopsy | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia | NCT00003735 | Leukemia | topotecan hydro... | - 21 Years | Children's Oncology Group | |
| A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | NCT05268003 | Acute Lymphobla... Leukemia | Ponatinib Venetoclax Mini-hyper CVD | 12 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | NCT00613457 | Leukemia | dexamethasone asparaginase Asparaginase cyclophosphamid... cytarabine daunorubicin doxorubicin Etoposide Ifosfamide mercaptopurine Methotrexate prednisone thioguanine Vincristine Vindesine | 1 Year - 17 Years | Associazione Italiana Ematologia Oncologia Pediatrica | |
| Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML | NCT01191801 | Acute Myeloid L... | vosaroxin + cyt... placebo + cytar... | 18 Years - | Sunesis Pharmaceuticals | |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | NCT04156256 | Hematologic Mal... Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Myeloid... | CD123-CD33 cCAR... | - | iCell Gene Therapeutics | |
| Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | NCT00176475 | Leukemia Lymphoma Multiple Myelom... | rituximab therapeutic all... | 18 Years - | Rutgers, The State University of New Jersey | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | NCT00003602 | Leukemia Myelodysplastic... | cytarabine etoposide idarubicin mitoxantrone hy... | 55 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia | NCT00004905 | Leukemia | filgrastim recombinant int... cyclophosphamid... cytarabine etoposide idarubicin peripheral bloo... radiation thera... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy | NCT03144583 | Leukemia Lymphoma | Adult different... | 2 Years - 80 Years | Institut d'Investigacions Biomèdiques August Pi i Sunyer | |
| STI571 in Treating Patients With Recurrent Leukemia | NCT00004932 | Leukemia | imatinib mesyla... | - 21 Years | Children's Oncology Group | |
| WT1 for the Detection of Minimal Residual Disease | NCT00179829 | Leukemia Cancer | WT 1 Testing | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia | NCT04172844 | Acute Myelogeno... | Azacitidine Venetoclax Pevonedistat | 18 Years - | Medical College of Wisconsin | |
| Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations | NCT01522469 | Relapsed or Ref... | Crenolanib Besy... | 18 Years - | Arog Pharmaceuticals, Inc. | |
| Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL) | NCT00500240 | Leukemia Lymphoma | Insulin Glargin... Insulin Aspart | 15 Years - | M.D. Anderson Cancer Center | |
| Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | NCT01593696 | ALL B Cell Lymphoma Leukemia Large Cell Lymp... Non-Hodgkin Lym... | Anti-Cluster of... | 1 Year - 30 Years | National Institutes of Health Clinical Center (CC) | |
| A Study in Participants With Acute Leukemia | NCT01214603 | Leukemia | LY2090314 | 18 Years - | Eli Lilly and Company | |
| Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies | NCT03262298 | Leukemia Lymphoma | Anti-CD22-CAR-t... | 18 Years - 65 Years | Affiliated Hospital to Academy of Military Medical Sciences | |
| Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents | NCT00111345 | Myeloid Leukemi... | Anthracyclines liposomal dauno... 2-CDA AI | 1 Day - 18 Years | University Hospital Muenster | |
| Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2 | NCT00896701 | Leukemia | flow cytometry immunologic tec... laboratory biom... | 15 Years - | Alliance for Clinical Trials in Oncology | |
| A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies | NCT01943851 | Neoplasms | GSK525762 | 18 Years - | GlaxoSmithKline | |
| Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia | NCT00004128 | Leukemia | aldesleukin filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00290004 | Chronic Lymphoc... Small Lymphocyt... Leukemia Lymphoma | motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention | NCT02592447 | Chronic Myeloge... | Therapy for Tar... Wait-List Contr... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | NCT00015951 | Leukemia Myelodysplastic... | bevacizumab cytarabine mitoxantrone hy... | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT00577694 | Leukemia | clofarabine gemtuzumab ozog... | 18 Years - 60 Years | UNC Lineberger Comprehensive Cancer Center | |
| Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia | NCT00003003 | Leukemia | sargramostim mitomycin C mitoxantrone hy... | 18 Years - 120 Years | Dartmouth-Hitchcock Medical Center | |
| Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) | NCT01444742 | Leukemia Myeloproliferat... | Clofarabine Cytarabine | 18 Years - | M.D. Anderson Cancer Center | |
| The Influence of TaKeTiNa Music Therapy, Traditional Chinese Acupuncture and Clown Theatrical Performance on Quality of Life and the Therapeutic Process of Patients Undergoing Allogenic Stem Cell Transplantation | NCT02976558 | Hematological N... Graft-Versus-Ho... Depression Stem Cell Trans... Quality of Life Leukemia | Clown theatrica... Acupuncture Music Therapy T... | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | NCT00924040 | Hairy Cell Leuk... | BL22 (CAT-3888) | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | NCT00004862 | Leukemia | filgrastim oblimersen sodi... cytarabine fludarabine pho... | 16 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | NCT00003619 | Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni... | filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo... | 19 Years - 90 Years | National Cancer Institute (NCI) | |
| Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia | NCT00436904 | Leukemia | Alemtuzumab Rituximab | 18 Years - | Mayo Clinic | |
| Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | NCT00357565 | Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo... | filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ... | - 3 Years | Masonic Cancer Center, University of Minnesota | |
| Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies | NCT04497701 | Lymphoma Leukemia | PEG-rhG-CSF gro... rhG-CSF group | - 18 Years | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | |
| Removing Transfusion Dependence as a Barrier to Hospice Enrollment | NCT05063591 | Hematologic Mal... Myelodysplastic... Acute Myeloid L... Lymphoma Leukemia Myeloma | Transfusion sup... | 18 Years - | Brown University | |
| Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | NCT00045513 | Leukemia Lymphoma | 7-hydroxystauro... fludarabine pho... | 18 Years - | University Health Network, Toronto | |
| Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) | NCT01392170 | Leukemia | PEG-IFNá-2a | 16 Years - | M.D. Anderson Cancer Center | |
| Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia | NCT02709083 | Chronic Myeloge... Chronic Myeloid... Leukemia | Dasatinib Imatinib Mesyla... Nilotinib | 17 Years - | Emory University | |
| Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | NCT01044069 | Leukemia Acute Lymphobla... | gene-modified T... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00519090 | Myelogenous Leu... | Imatinib Nilotinib (AMN1... | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
